| Budget Amount *help |
¥19,630,000 (Direct Cost: ¥15,100,000、Indirect Cost: ¥4,530,000)
Fiscal Year 2014: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2013: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2012: ¥10,270,000 (Direct Cost: ¥7,900,000、Indirect Cost: ¥2,370,000)
|
|---|
| Outline of Final Research Achievements |
We conducted a comprehensive genome analysis of 97 cases of lung adenocarcinoma and explore the mutated protein kinases those could be potential therapeutic targets. All the cases harbored one or more altered kinase or related genes involved in cell proliferation. To establish a cell line-based experimental system that represents the diversity of lung adenocarcinoma, comprehensive genome and epigenome data of 26 cell lines were collected and these data are open for public at our database (http://dbtss.hgc.jp/). We found that LC-2/ad cells express the CCDC6-RET fusion gene and a RET-targeting compound, vandetanib exhibited anti-tumor effect. These findings and experiences encouraged us and other researchers to establish a nation-wide lung cancer genome screening platform and to accomplish investigator-initiated clinical trials targeting lung cancers with rare driver mutations/alterations.
|
